1986

International Committee on the Taxonomy of Viruses rebuffed Robert Gallo (HTLV-III) and agreed on a new name for the retrovirus causing AIDS: HIV, human immunodeficiency virus (Epstein, 77). Phase II trial of AZT ended early because “the drug was so effective that it would be unethical to keep the control group on placebos any longer” (Epstein, 198). On 20 March 1987, FDA approved AZT for use by the 33,000 Americas with AIDS (199).